Navigation Links
ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
Date:12/20/2007

IRVINE, Calif., Dec. 20 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced today the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Xibrom(TM) QD (once-daily). The Company is seeking approval for Xibrom QD as a treatment for inflammation, pain, and photophobia following cataract surgery.

Xibrom(TM) (bromfenac ophthalmic solution)

Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for inflammation and reduction of pain following cataract surgery. Xibrom is the fastest growing ophthalmic product in 2007, according to IMS data. Xibrom, under a different trade name but identical formulation, was launched in Japan in 2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights for Xibrom in 2002 and launched the product in the U.S. in 2005.

ABOUT ISTA PHARMACEUTICALS

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism ... diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering ... analysis (ABA) is key to providing effective treatment for individuals with ASD. Now, ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast ... Hung to the company´s Board of Directors. , “We are honored to ... an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge ...
(Date:2/9/2016)... ... ... Dr. Rassouli, cosmetic dentist in Orange County , is now offering ... procedures in dentistry today, but the cost often leads to patients looking to less ... whitening-related damage. For a limited time, Dr. Rassouli is offering this special whitening package ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016 The new report "Global Blood Monitoring & Cardiac Monitoring ... & Consulting group reveals that global market for blood monitoring & ... and expected to grow to US$ 24,830.1 million by 2019 at ... North America , Europe , ... Middle-East and Africa . The three ...
(Date:2/9/2016)... Feb. 9, 2016  Johnson & Johnson (NYSE: ... Global Healthcare Conference on Tuesday, Feb. 23, at the ... Caruso , Vice President, Finance & Chief Financial Officer ... represent the Company in a session scheduled at 10:00 ... --> www.investor.jnj.com . --> This webcast ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will ... product line for long-term implant applications and announce ... Design & Manufacturing (MD&M) West Conference (Booth #1759), ... --> --> Available ... Biomedical LSRs offer outstanding physical properties enabling our ...
Breaking Medicine Technology: